autologous cultured chondrocytes on porcine collagen membrane
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chondral Defect
Conditions
Chondral Defect, Articular Cartilage Defect
Trial Timeline
Mar 1, 2026 → Jul 1, 2030
NCT ID
NCT06915233About autologous cultured chondrocytes on porcine collagen membrane
autologous cultured chondrocytes on porcine collagen membrane is a phase 3 stage product being developed by Vericel for Chondral Defect. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06915233. Target conditions include Chondral Defect, Articular Cartilage Defect.
What happened to similar drugs?
0 of 1 similar drugs in Chondral Defect were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06915233 | Phase 3 | Recruiting |
| NCT01251588 | Pre-clinical | Completed |
| NCT00719576 | Phase 3 | Completed |
Competing Products
1 competing product in Chondral Defect
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MACI | Vericel | Phase 3 | 41 |